Most Read Articles
2 days ago
No association exists between physical activity and the risk of urological cancer, according to a population-based prospective study in Japan.
12 Feb 2019
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
3 days ago
Patients with childhood-onset inflammatory bowel disease are more likely to die than the general population, a study suggests.
3 days ago
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.

Norfloxacin yields survival gains in certain patients with advanced cirrhosis

01 Oct 2018

The fluoroquinolone norfloxacin does not appear to reduce 6-month mortality in patients with advanced cirrhosis, according to a study. However, the drug confers survival benefits among those with low ascites fluid protein concentrations.

A total of 291 adult patients with Child-Pugh class C cirrhosis who had not received recent fluoroquinolone therapy were randomized to treatment with norfloxacin 400 mg (n=144) or placebo (n=147) once-daily for 6 months.

Patients were evaluated monthly for the first 6 months and at 9 and 12 months thereafter. The primary endpoint was 6-month mortality, estimated by the Kaplan-Meier method, which censored spontaneous bacterial peritonitis, liver transplantation or loss during follow up.

The 6-month mortality estimate did not differ significantly between the two treatment groups, 14.8 percent with norfloxacin vs 19.7 percent with placebo (p=0.21).

However, competing risk analysis taking liver transplantation into account showed that the cumulative incidence of death at 6 months was less common in the norfloxacin group than in the placebo group (subdistribution hazard ratio [SHR], 0.59; 95 percent CI, 0.35–0.99).

The protective effect of the drug on the risk of death at 6 months was pronounced among patients with lower ascites fluid protein concentrations (<15 g/L; SHR, 0.35; 0.13–0.93) and absent among those with higher ascites fluid protein concentrations (15 g/L; SHR, 1.39; 0.42–4.57).

Norfloxacin substantially reduced the incidence of any and Gram-negative bacterial infections without increasing infections caused by Clostridium difficile or multiresistant bacteria. This suggests that the drug may prevent some infections, but not the development of spontaneous bacterial peritonitis and other noninfectious, liver-related complications, as researchers pointed out.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
No association exists between physical activity and the risk of urological cancer, according to a population-based prospective study in Japan.
12 Feb 2019
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
3 days ago
Patients with childhood-onset inflammatory bowel disease are more likely to die than the general population, a study suggests.
3 days ago
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.